EyePoint Pharmaceuticals, Inc. - EYPT STOCK NEWS

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the issuance of non-statutory stock options to five new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4).

The grants, approved by the Compensation Committee, were made outside the 2023 Long-Term Incentive Plan.

A total of 25,000 shares of common stock were granted, with an exercise price of $9.38 per share, the closing price on June 14, 2024, the date of the grant.

The options vest over four years, with 25% vesting on the first anniversary of the grant date, and the remainder vesting monthly over the next three years, contingent on continued employment.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that its President and CEO, Jay S. Duker, M.D., will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 12, 2024, at 3:20 p.m. ET. The presentation will be webcast live and available for replay for 90 days via EyePoint’s investor webpage. EyePoint is dedicated to developing and commercializing therapies for serious retinal diseases, aiming to enhance patient lives.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the granting of non-statutory stock options to four new employees as inducement awards outside the company's 2023 Long-Term Incentive Plan, adhering to NASDAQ Listing Rule 5635(c)(4). The grants, approved by the Compensation Committee, involve options to purchase a total of 44,200 shares of common stock. These options were issued on May 15, 2024, at an exercise price of $12.94 per share, the closing price of the stock on that date. The options have a ten-year term and vest over four years, with 25% vesting after the first year and the rest in monthly installments over the next three years, contingent on continued employment.

EyePoint Pharmaceuticals reported financial results for the first quarter of 2024 and highlighted recent corporate developments. The company has $299 million in cash and investments as of March 31, 2024, ensuring cash runway through Phase 3 trials for DURAVYU for wet AMD in 2026. Despite the Phase 2 PAVIA trial not meeting the primary endpoint, DURAVYU showed a biologic effect in patients with NPDR. EyePoint plans to initiate the Phase 3 LUGANO trial for DURAVYU in wet AMD and present Phase 2 VERONA trial data in 2025.

EyePoint Pharmaceuticals announced topline results of the Phase 2 PAVIA trial evaluating DURAVYU in patients with non-proliferative diabetic retinopathy (NPDR). Although the trial did not meet the primary endpoint, DURAVYU demonstrated a favorable safety profile and potential in reducing NPDR progression at nine months. The Company plans to review full 12-month data to determine the future path for DURAVYU. Dr. Duker expressed optimism for DURAVYU's potential as a maintenance therapy for wet AMD patients based on positive data from DAVIO 2.

EyePoint Pharmaceuticals granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 50,500 shares of EyePoint Pharmaceuticals common stock to seven new employees on April 15, 2024, with an exercise price of $21.28 per share. The options have a ten-year term and vest over four years, subject to the employee’s continued service with the company.

EyePoint Pharmaceuticals appoints leading ophthalmologists to its Scientific Advisory Board, including co-chair Charles Wykoff, M.D., Ph.D. The company gears up for global Phase 3 clinical trials for EYP-1901 in wet AMD, with the FDA conditionally accepting the trade name DURAVYU. EyePoint aims to initiate Phase 3 pivotal trial LUGANO for DURYVU in wet AMD in the second half of 2024.

EyePoint Pharmaceuticals (EYPT) granted non-statutory stock options to new employees outside the 2023 Long-Term Incentive Plan. The Company awarded 77,000 shares to six employees with an exercise price of $21.48 per share. The options have a ten-year term and vest over four years. Vesting is subject to continued service with the Company.

EyePoint Pharmaceuticals, Inc. (EYPT) announces positive Phase 2 trial results for EYP-1901 in wet AMD, with plans for Phase 3 trials. Cash and investments at $331M. Key appointment of Chief Medical Officer. Dosed first patient in Phase 2 trial for DME.